{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:10:17Z","timestamp":1790939417823,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deficiency of ADAMTS13 is found in patients with thrombotic thrombocytopenic purpura (TTP), and the genetic defects in the ADAMTS13 gene or the autoantibody against ADAMTS13 is thought to be responsible for the development of TTP. The clinical correlation and mechanisms of secondary ADAMTS13 deficiency in other disease states were investigated. In addition to TTP, ADAMTS13 levels were severely decreased in patients with sepsis-induced disseminated intravascular coagulation (DIC). The incidence of acute renal failure and serum creatinine levels in patients with ADAMTS13 activity levels lower than 20% (incidence, 41.2%; creatinine, 160 \u00b1 150 \u03bcM [1.81 \u00b1 1.70 mg\/dL]) (P &lt; .05) were significantly higher than they were in patients with ADAMTS13 activity levels higher than 20% (incidence, 15.4%; creatinine, 84 \u00b1 67 \u03bcM [0.95 \u00b1 0.76 mg\/dL]) (P &lt; .01). Additionally, unusually large von Willebrand factor multimers were detected in 26 (51.0%) of 51 patients with ADAMTS13 activity levels lower than 20%. Lower molecular weight forms of ADAMTS13 were found in the plasma of patients with sepsis-induced DIC, suggesting that the deficiency of ADAMTS13 was partially caused by its cleavage by proteases in addition to decreased synthesis in the liver. These data suggested that severe secondary ADAMTS13 deficiency can be associated with sepsis-induced DIC and may contribute to the development of renal failure.<\/jats:p>","DOI":"10.1182\/blood-2005-03-1087","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T03:33:43Z","timestamp":1127878423000},"page":"528-534","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":334,"title":["Severe secondary deficiency of von Willebrand factor\u2013cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure"],"prefix":"10.1182","volume":"107","author":[{"given":"Tomoko","family":"Ono","sequence":"first","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Mimuro","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Madoiwa","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Soejima","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kashiwakura","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishiwata","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Takano","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ohmori","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Sakata","sequence":"additional","affiliation":[{"name":"From the Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken, Japan; the Research and Development Department, Mitsubishi Kagaku Iatron, Chiba-ken, Japan; and the Chemo-Sero Therapeutic Research Institute, Kumamoto-ken, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111815432200500_REF1","doi-asserted-by":"crossref","unstructured":"Gerritsen HE, Robles R, La\u0308mmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98: 1654-1661.","DOI":"10.1182\/blood.V98.6.1654"},{"key":"2019111815432200500_","doi-asserted-by":"crossref","unstructured":"Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of metalloprotease family. Blood. 2001;98: 1662-1666.","DOI":"10.1182\/blood.V98.6.1662"},{"key":"2019111815432200500_","doi-asserted-by":"crossref","unstructured":"Levy GG, Nicholas WC, Lian EC, et al. Mutation in a member of ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413: 488-494.","DOI":"10.1038\/35097008"},{"key":"2019111815432200500_","doi-asserted-by":"crossref","unstructured":"Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276: 41059-41063.","DOI":"10.1074\/jbc.C100515200"},{"key":"2019111815432200500_REF5","doi-asserted-by":"crossref","unstructured":"Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo). 2001;130: 475-480.","DOI":"10.1093\/oxfordjournals.jbchem.a003009"},{"key":"2019111815432200500_REF6","doi-asserted-by":"crossref","unstructured":"Moake JL Thrombotic microangiopathies. N Engl J Med. 2002;347: 589-600.","DOI":"10.1056\/NEJMra020528"},{"key":"2019111815432200500_","doi-asserted-by":"crossref","unstructured":"Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87: 4223-4234.","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223"},{"key":"2019111815432200500_REF8","doi-asserted-by":"crossref","unstructured":"Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med. 1998;339: 1578-1584.","DOI":"10.1056\/NEJM199811263392202"},{"key":"2019111815432200500_REF9","doi-asserted-by":"crossref","unstructured":"Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339: 1585-1594.","DOI":"10.1056\/NEJM199811263392203"},{"key":"2019111815432200500_REF10","doi-asserted-by":"crossref","unstructured":"Loof AH, van Vliet HH, Kappers-Klunne MC. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol. 2001;112: 1087-1088.","DOI":"10.1046\/j.1365-2141.2001.02622-5.x"},{"key":"2019111815432200500_","doi-asserted-by":"crossref","unstructured":"Veyradier A, Brivet F, Wolf M, et al. Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome. Hematol J. 2001;2: 352-354.","DOI":"10.1038\/sj.thj.6200126"},{"key":"2019111815432200500_REF12","doi-asserted-by":"crossref","unstructured":"Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS-13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100: 778-785.","DOI":"10.1182\/blood-2001-12-0166"},{"key":"2019111815432200500_REF13","doi-asserted-by":"crossref","unstructured":"Studt JD, Bohm M, Budde U, Girma JP, Varadi K, La\u0308mmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay. J Thromb Haemost. 2003;1: 1882-1887","DOI":"10.1046\/j.1538-7836.2003.00385.x"},{"key":"2019111815432200500_REF14","doi-asserted-by":"crossref","unstructured":"Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002;99: 11902-11907.","DOI":"10.1073\/pnas.172277399"},{"key":"2019111815432200500_REF15","doi-asserted-by":"crossref","unstructured":"Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002;30: 1729-1734","DOI":"10.1097\/00003246-200208000-00009"},{"key":"2019111815432200500_REF16","doi-asserted-by":"crossref","unstructured":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20: 864-874.","DOI":"10.1097\/00003246-199206000-00025"},{"key":"2019111815432200500_REF17","doi-asserted-by":"crossref","unstructured":"Ko\u0308hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256: 495-497.","DOI":"10.1038\/256495a0"},{"key":"2019111815432200500_REF18","doi-asserted-by":"crossref","unstructured":"Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich\/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102: 3232-3237.","DOI":"10.1182\/blood-2003-03-0908"},{"key":"2019111815432200500_REF19","doi-asserted-by":"crossref","unstructured":"Ono T, Sogabe M, Ogura M, Furusaki F. Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem. 2003;49: 987-989.","DOI":"10.1373\/49.6.987"},{"key":"2019111815432200500_REF20","doi-asserted-by":"crossref","unstructured":"Kohno I, Inuzuka K, Itoh Y, et al. A monoclonal antibody specific to the granulocyte-derived elastase-fragment D species of human fibrinogen and fibrin: its application to the measurement of granulocyte-derived elastase digests in plasma. Blood. 2000;95: 1721-1728.","DOI":"10.1182\/blood.V95.5.1721.005k13_1721_1728"},{"key":"2019111815432200500_REF21","doi-asserted-by":"crossref","unstructured":"Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105: 1085-1093.","DOI":"10.1182\/blood-2004-03-1101"},{"key":"2019111815432200500_REF22","doi-asserted-by":"crossref","unstructured":"Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. von Willebrand factor cleaving protease (ADAMTS-13): in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100: 710-713.","DOI":"10.1182\/blood-2002-02-0344"},{"key":"2019111815432200500_REF23","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Change in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98: 2730-2735.","DOI":"10.1182\/blood.V98.9.2730"},{"key":"2019111815432200500_REF24","doi-asserted-by":"crossref","unstructured":"Dong J, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100: 4033-4039.","DOI":"10.1182\/blood-2002-05-1401"},{"key":"2019111815432200500_REF25","doi-asserted-by":"crossref","unstructured":"Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004;44: 146-150.","DOI":"10.1111\/j.1537-2995.2004.00626.x"},{"key":"2019111815432200500_REF26","doi-asserted-by":"crossref","unstructured":"Galbusera M, Ruggenenti P, Noris M, et al. \u03b11-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet. 1995;345: 224-225.","DOI":"10.1016\/S0140-6736(95)90224-4"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/528\/1279707\/zh800206000528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/528\/1279707\/zh800206000528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:27:06Z","timestamp":1586474826000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/528\/131443\/Severe-secondary-deficiency-of-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1087","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}